NICE discontinued producing new Medtech innovation briefings

In May 2023, NICE announced that the Medtech innovation briefing (MIB) program was discontinued. MIBs were a part of the advice program at NICE. They do not contain any recommendations while providing information on new medical technologies (such as description, application, potential role in the treatment pathway, a review of relevant published evidence, and the likely costs of using the technology).

NICE will now focus on expanding the production of new health technology guidance and introducing new approaches to evaluating the most promising health technologies that meet the needs of the NHS and patients (piloted as an early value assessment approach). This will enable “conditional recommendations” for use while further evidence is generated (where appropriate) to accelerate access to the technology for clinicians and patients.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.